Rare Disease Day: Updates on Rett Syndrome and Pompe DiseaseFebruary 28th 2023
In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.
The Potential of Blood Tests to Improve Screening and Monitoring in Alzheimer Disease Clinical Trials: Ronald C. Petersen, MD, PhDFebruary 16th 2023
The director of the Alzheimer’s Disease Research Center at Mayo Clinic detailed the current issues with access and affordability to critical biomarkers in the screening and monitoring of patients in Alzheimer disease trials. [WATCH TIME: 3 minutes]
NeuroVoices: Ronald C. Petersen, MD, PhD, on Redefining Clinically Meaningful Benefit in Alzheimer Drug DevelopmentFebruary 15th 2023
The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided insight on new considerations for interpreting data from cognitive and functional measures in trials assessing agents for Alzheimer disease.
Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials: Ronald C. Petersen, MD, PhDFebruary 12th 2023
The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]
Gaining a Better Understanding of Clinical Benefit in Alzheimer Disease: Ronald C. Petersen, MD, PhDFebruary 9th 2023
The director of the Alzheimer’s Disease Research Center at Mayo Clinic discussed a recently published paper focused on the expectations and clinical meaningfulness of randomized controlled trials in Alzheimer disease. [WATCH TIME: 4 minutes]
Eptinezumab Shows Positive Effects on Patient-Reported Outcomes in Medication-Overuse Headache from Chronic MigraineJanuary 31st 2023
After 12 weeks of treatment, almost twice as many patients on eptinezumab reported either “much improved” or “very much improved” than those on placebo, according to Patient Global Impression of Change.
SRNA Roundtable Discussion: Diagnosis, Presentation, and Treatment Decision Differences Among Rare Neuroimmune DisordersOctober 3rd 2022
Experts such as Brenda Banwell, MD; Sean Pittock, MD; and Michael Levy, MD, PhD, cover topics related to differences in rare neuroimmune disorders, how they're approached and treated.
The Role of Preeclampsia and Inflammation in Late-Life Cognition: Vesna Garovic, MD, PhDAugust 29th 2022
The chair of the nephrology division at Mayo Clinic provided context on recent findings linking inflammation and neurovascular damage in women with a history of severe preeclampsia, and how the community may react. [WATCH TIME: 2 minutes]
Raising the Awareness of Severe Preeclampsia and Recognizing Potential Long-Term ImpactsAugust 13th 2022
Vesna Garovic, MD, PhD, chair of the nephrology division at Mayo Clinic, discussed the appropriate reaction to data suggesting late-life elevated inflammation and neurovascular damage from severe preeclampsia.
Understanding the Cognitive Risks With Preeclampsia and Raising Awareness: Vesna Garovic, MD, PhDAugust 11th 2022
The chair of the nephrology division at Mayo Clinic discussed the major questions surrounding preeclampsia and its long-term effects, as well as whether new findings change the way clinicians treat patients with the condition. [WATCH TIME: 4 minutes]
NeuroVoices: Vesna Garovic, MD, PhD, on Severe Preclampsia’s Effect on Late-Life Cognition, Neuroinflammation for WomenAugust 10th 2022
The chair of the nephrology division at Mayo Clinic provided context on new findings on the risks of preeclampsia, a hypertensive disorder, and elevated levels of neuroinflammation and neurovascular damage.
Understanding the Neuropathological Link Between Preeclampsia and Neuroinflammation, Neurovascular Damage: Vesna Garovic, MD, PhDAugust 5th 2022
The nephrologist at Mayo Clinic provided insight on new data showing elevated extracellular vesicles of neurovascular origin in women with a history of severe preeclampsia years after pregnancy. [WATCH TIME: 4 minutes]
Severe Preeclampsia During Pregnancy Linked With Late-Life Cognitive Issues, InflammationAugust 4th 2022
Inflammatory coagulation pathway activator positive extracellular vesicles were significantly increased in women with a history of severe preeclampsia compared with controls and those with milder cases.
Technological Advancements Improving, Expanding Capabilities of Antibody Testing: Sean Pittock, MDJuly 17th 2022
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]
Utilizing the Mayo Clinic 3-M Approach for Different Autoimmune Disorder Presentations: Sean Pittock, MDJuly 7th 2022
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided insight on a unique way the institution cares for patients who present with an inflammatory or autoimmune entity. [WATCH TIME: 5 minutes]
Distinguishing and Diagnosing Various Presentations of Autoimmune Encephalitis: Sean Pittock, MDJuly 5th 2022
The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the complexities in diagnosing autoimmune encephalitis and the approach needed to be taken. [WATCH TIME: 5 minutes]
Pioneering Care for Autoimmune Disorders Through Research and Results: The Mayo Clinic WayJune 29th 2022
Through dedicated research into biomarker discovery and patient care, the neuroimmunology laboratory at Mayo Clinic has paved a new way of life for those with autoimmune disorders.
The Aducanumab Saga and the Future of Antiamyloid Monoclonal AntibodiesJune 13th 2022
The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus RecurrenceJune 11th 2022
Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.
The Incidence of and Difficulties in Defining Status Migrainosus: Rashmi Halker Singh, MD, FAHS, FAANJune 10th 2022
The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]
Building the Next Generation of Migraine Specialists: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHSApril 21st 2022
The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]
Top Priorities Within the Migraine Field: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHSApril 18th 2022
The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology discussed some of the key research needs for migraine care going forward. [WATCH TIME: 3 minutes]